GSK and SCYNEXIS announce agreement to commercialise and further develop Brexafemme
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
70+ CXOs from leading healthcare institutions across India attended the confluence at Mumbai
Expands robotics to 20+ specialities
Plantasens Pro LM is 100% natural, readily biodegradable, COSMOS and Natrue certified
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Subscribe To Our Newsletter & Stay Updated